Integrative systems of genomic risk markers for cancer and other diseases: Future of predictive medicine

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 131-135

  Yuzhalin, Arseniy E ^a   Kutikhin, Anton G ^a  

^a KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Biomarkers; Cancer; Cancer prevention; Single nucleotide polymorphisms

Indexed keywords

BIOLOGICAL MARKER; PATTERN RECOGNITION RECEPTOR;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CHRONIC INFLAMMATION; DNA POLYMORPHISM; DNA REPAIR; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENOME ANALYSIS; HUMAN; IMMUNE SYSTEM; MALIGNANT NEOPLASTIC DISEASE; PERSONALIZED MEDICINE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84864041813     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S30855     Document Type: Article

References (17)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Zineh I, Huang SM. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark Med. 2011;5:705-713.
3. On beyond GWAS. Editorial. Nature Genetics. 2010;42(7):551.
4. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-933.
5. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003;12:205-216.
6. Tsigris C, Chatzitheofylaktou A, Xiromeritis C, Nikiteas N, Yannopoulos A. Genetic association studies in digestive system malignancies. Anticancer Res. 2007;27:3577-3587.
7. Lodish H, Berk A, Matsudaira P, et al. Molecular Biology of the Cell, 5th ed. New York, NY: WH Freeman; 2004.
8. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
9. Varfolomeev E, Vucic D. Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 2011;7:633-648.
10. Weinberg RA. The Biology of Cancer. New York, NY: Garland Science; 2007.
11. Piao JM, Kim HN, Song HR, et al. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer. 2011;S73: 264-267.
12. Huang CY, Su CT, Chu JS, et al. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area. Toxicol Appl Pharmacol. 2011;257:349-355.
13. Kutikhin AG, Yuzhalin AE. Inherited variation in pattern recognition receptors and cancer: dangerous liaisons? Cancer Manag Res. 2012;4:31-38.
14. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer. 2006;118:129-138.
15. McLean MH, El-Omar EM. Genetics of inflammation in the gastrointestinal tract and how it can cause cancer. Recent Results Cancer Res. 2011;185:173-183.
16. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22:83-89.
17. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183:4169-4175.